NEW YORK (
CHANGE IN RATINGS
was upgraded to buy at TheStreet Ratings.
(MSFT - Get Report)
was upgraded at Nomura to buy. $38 price target. Shareholder activism could help unlock value, Nomura said.
(PCP - Get Report)
was upgraded at Wells Fargo to outperform from market perform. Company can deliver 15% annual earnings growth over the next several years, Wells Fargo said.
was initiated with an outperform rating at Oppenheimer. $300 price target. Eylea should continue to grow and the company is expanding into DME, Oppenheimer said.
was downgraded at Leerink Swann to market perform from outperform. $26 price target. Valuation call, as the company trades at a sizable premium to its peers, Leerink Swann said.
was initiated with a buy rating at Keybanc. $100 price target. Company has a strong growth profile, including exposure to Latin America, Keybanc said.
was downgraded to hold at TheStreet Ratings.
(TSLA - Get Report)
was initiated with a hold rating at Stifel Nicolaus. Valuation call, as the company still has little evidence of customer retention or success at lower price points, Stifel Nicolaus said.
(VRTX - Get Report)
was initiated with an outperform rating at Oppenheimer. $105 price target. Cystic Fibrosis treatments can continue to drive growth, Oppenheimer said.
(ZNGA - Get Report)
was initiated with a hold rating at Benchmark. $2.98 price target. New management needs to show stabilized Web trends and material mobile acceleration, Benchmark said.
Stock Comments / EPS Changes
numbers were cut at BMO Capital. Estimates were reduced through 2014. Management cut guidance, BMO Capital said. Market Perform rating and new $15 price target.
numbers were increased at UBS. Estimates were boosted through 2015. Domestic business is positioned well, ahead of the holidays, UBS said. Neutral rating and new $35 price target.
numbers were reduced at BMO Capital. Shares are now seen reaching $27. Estimates were also cut, given lower operating growth, especially in the enterprise segment, BMO Capital said. Market Perform rating.